Search PubMed⌕ Search

Biomedical subjects

B Kommerell

Publications and source records attributed to B Kommerell.

225 records · Page 13Linked to original sources
PubMedDate not supplied

Ethanol and intestinal carcinogenesis in the rat.

The effect of chronic ethanol administration on 1,2-dimethylhydrazine induced rectal carcinogenesis was investigated in 32 paired male Sprague-Dawley rats fed a nutritionally adequate liquid diet containing 36% of total calories either as ethanol or isocaloric carbohydrates. Chronic ethanol ingestion increased the total number of rectal tumors significantly (17 vs. 6, p less than 0.02), whereas no cocarcinogenic effect of ethanol was observed in other parts of the intestine. Alcohol did not influence tumor size or histopathology. A 47% increase in the activity of mucosal alcohol dehydrogenase in the distal colorectum was found between chronically ethanol fed and pair fed controls (0.241 +/- 0.019 vs. 0.164 +/- 0.020 mumol mg protein-1 hr-1, p less than 0.01). This could in part explain the cocarcinogenic effect of alcohol in this tissue. The data give experimental support to the epidemiologic findings of an increased incidence of rectal cancer in the alcoholic.

1,2-Dimethylhydrazine↗
PubMedDate not supplied

Prevalence and serological manifestation of hepatitis C virus infection in patients with hepatitis non-A, non-B: a follow-up study.

OBJECTIVES: Sera of patients with acute hepatitis non-A, non-B prospectively followed for a mean of 11.4 years (range 9 to 15 years) were assayed for anti-hepatitis C virus (HCV) by first- and second-generation enzyme-linked immunosorbent assay (ELISA) and second-generation recombinant immunoblot assay (RIBA) to study the patterns of antibody response in relation to the outcome of disease. METHODS: From 1974 through 1981, 112 patients with acute hepatitis non-A, non-B were enrolled in a prospective study. Sera of 45 patients taken during the acute phase of hepatitis, as well as taken during follow-up in 1983 and 1990 were still available for evaluation. Sera were assayed by first- (ELISA-1) and second-generation (ELISA-2) anti-HCV ELISA, second-generation RIBA (RIBA-2) and HCV RNA by RT-polymerase chain reaction (PCR). RESULTS: Based on anti-HCV seropositivity by RIBA-2 in acute hepatitis and/or during follow-up, a total of 22/45 patients with HNANB (48.8%) were considered to have confirmed HCV infection. By ELISA-1, 11/22-patients with HCV infection (50%) were positive for anti-HCV within 6 weeks of the onset of illness, 18/22 sera (82%) were reactive by ELISA-2. Confirmation by RIBA-2 was obtained in 12 (55%) cases, while one additional patient was RIBA-2 indeterminate. In 1983, a disappearance of anti-HCV tested by RIBA-2 was observed in 7/12 resolved patients but in none of the patients with chronic hepatitis (p = 0.0018) while loss of anti-HCV was observed in 2/12 cases with resolved hepatitis and none with chronic hepatitis by ELISA (not significant). In 1990, all patients with chronic hepatitis were still positive by either ELISA or RIBA-2 but 9/12 (75%), 6/12 (50%) and 10/11 (91%) patients with resolved hepatitis had lost anti-HCV seropositivity tested by ELISA-1 (p = 0.0004), ELISA-2 (p = 0.0124) or RIBA-2 (p < 0.0001), respectively. Mostly, RIBA-2 reactivity was lost prior to ELISA-2 reactivity during follow-up. Rates of antibody loss as detected by ELISA-1, ELISA-2 and RIBA-2 were 4.1, 2.9 and 5.8 per 100 person years, respectively. CONCLUSIONS: This study shows that the continuing presence of HCV is necessary to maintain anti-HCV seropositivity. In contrast, anti-HCV reactivity is progressively lost over time in resolved patients. In addition, albeit more specific, the RIBA-2 is less sensitive than the ELISA and RIBA seroconversion to negative seems to be the earliest serological marker of a resolved HCV infection.

Adult↗